Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7934)	5/7/2000 11:58:00 AM
From: Spekulatius	Respond to of 9719

I don't necessary expect the positive trend to continue, Greenspan will IMHO raise the interest rates .5% but more important will be his comment regarding further raises. It seems that the market expects a comment that further raises are less likely and I do not think that Greenspan will do that. The inflation ghost clearly came out of the closet last quarter and Greenspan will have to fight it. I still think a NASDAQ at 3000 is quite possible, and the Biotechs will react negatively. Many of the bigger Biotechs have rebounded nicely but the smaller ones have fallen into the liquidity trap.

To: Vector1 who wrote (7934)	5/7/2000 12:18:00 PM
From: Spekulatius	Read Replies (2) \| Respond to of 9719

Biochem - I like the progress they have made during the last year. Here are their milestones (taken from the annual report) - Zeffix has disappointed first but is now gaining strong momentum - dOTC came back from a near death experience as a single enantiomer (-) dOTC (Hello Sepracor!) - Niche drug PACIS approved for bladder cancer - BCH-3963 (pain control) and Toxacitabine (cancer)in Phase II - An ambitous recombinant protein vaccine program with the Canadian government kicking in CAN $80M - A stock buyback and new collaborations have reduced dependency from Glaxo/Wellcome - sold the noncore diagnostics and some vaccine operations - investments in genomics ventures pay rich dividends I still think that the Phase II pipeline looks somewhat weak but Biochem clearly has made significant progress in developing its business. I hope this post is not considered a spam :-).